Project: GLYCex: A novel therapeutic strategy to fight glycolytic cancers
| Acronym | GLYCex (Reference Number: 113882) |
| Duration | 01/04/2020 - 01/04/2023 |
| Project Topic | Our goal is to market a drug providing a treatment option for glycolytic, i.e. the majority of aggressive cancers. We will advance an innovative chemical lead with strong in vitro effect into a drug candidate, ready for clinical phase I studies. In-vivo effects will be shown by using xenografts generated from patients with aggressive tumours. We will investigate the correlation between drug candidate efficacy and tumour molecular phenotype to develop a companion biomarker for patient selection. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 12 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Arctic | Coordinator | Norway |
| 2 | XenTech | Partner | France |